DaVita (DVA)
(Delayed Data from NYSE)
$148.88 USD
+3.04 (2.08%)
Updated Aug 14, 2024 04:00 PM ET
After-Market: $149.50 +0.62 (0.42%) 7:58 PM ET
1-Strong Buy of 5 1
A Value C Growth B Momentum A VGM
Brokerage Reports
DaVita Inc. [DVA]
Reports for Purchase
Showing records 261 - 280 ( 289 total )
Company: DaVita Inc.
Industry: Medical - Outpatient and Home Healthcare
Company: DaVita Inc.
Industry: Medical - Outpatient and Home Healthcare
Company: DaVita Inc.
Industry: Medical - Outpatient and Home Healthcare
Company: DaVita Inc.
Industry: Medical - Outpatient and Home Healthcare
Company: DaVita Inc.
Industry: Medical - Outpatient and Home Healthcare
Company: DaVita Inc.
Industry: Medical - Outpatient and Home Healthcare
STOCKS WITH EXCEPTIONAL APPRECIATION OPPORTUNITY ONCE THE OVERALL MARKET STABILIZES
Provider: FELTL & COMPANY
Company: DaVita Inc.
Industry: Medical - Outpatient and Home Healthcare
Company: DaVita Inc.
Industry: Medical - Outpatient and Home Healthcare
Increasing estimates and price target on strong 2Q results
Provider: FELTL & COMPANY
Analyst: WEIGHT M
Company: DaVita Inc.
Industry: Medical - Outpatient and Home Healthcare
Company: DaVita Inc.
Industry: Medical - Outpatient and Home Healthcare
FDA removes targeted Hb range for ESA?s, should drive further dosing declines
Provider: FELTL & COMPANY
Analyst: WEIGHT M
Company: DaVita Inc.
Industry: Medical - Outpatient and Home Healthcare
Survey sees further opportunity to reduce patient costs; near-term margin expansion?
Provider: FELTL & COMPANY
Company: DaVita Inc.
Industry: Medical - Outpatient and Home Healthcare
Company: DaVita Inc.
Industry: Medical - Outpatient and Home Healthcare
1Q: Strong quarterly results; guidance sets floor for next two years
Provider: FELTL & COMPANY
Analyst: HAYNOR B
Company: DaVita Inc.
Industry: Medical - Outpatient and Home Healthcare
Company: DaVita Inc.
Industry: Medical - Outpatient and Home Healthcare
4Q: impressive cost reductions, we expect more in 2011, outlook better than ever
Provider: FELTL & COMPANY
Analyst: HOERNEMANN J
Company: DaVita Inc.
Industry: Medical - Outpatient and Home Healthcare
Company: DaVita Inc.
Industry: Medical - Outpatient and Home Healthcare
Facility survey: Changes are underway and more diverse than expected
Provider: FELTL & COMPANY
Analyst: HOERNEMANN J
Company: DaVita Inc.
Industry: Medical - Outpatient and Home Healthcare
2011 Top Ideas.
Provider: FELTL & COMPANY
Company: DaVita Inc.
Industry: Medical - Outpatient and Home Healthcare
Transition relief? It?s possible, but we remain skeptical
Provider: FELTL & COMPANY
Analyst: HOERNEMANN J
Company: DaVita Inc.
Industry: Medical - Outpatient and Home Healthcare
3Q 2010 very good quarter overshadowed by international expansion plans, bundle prep
Provider: FELTL & COMPANY
Analyst: HOERNEMANN J